Form 4: Lixte Biotechnology Director Yun Yen Reports Stock Option Grant in Lieu of Cash Compensation
SEC Form 4
Director Yun Yen reports receiving stock options for 5,786 shares of Lixte Biotechnology in lieu of quarterly cash compensation on September 30, 2024.
Summary
- On September 30, 2024, Yun Yen, a director of Lixte Biotechnology Holdings, Inc., was granted options to purchase 5,786 shares of common stock.
- These options were granted in lieu of quarterly cash compensation under the Board Compensation Plan.
- The options have an exercise price of $1.30 and vest immediately.
- Yen also holds other options and warrants to purchase Lixte Biotechnology common stock at various exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reflects a standard compensation practice. The grant of options in lieu of cash could be seen as slightly positive for the company's cash flow management.
Positives
- The grant of stock options in lieu of cash compensation may conserve the company's cash resources.
Industry Context
This filing is a routine disclosure related to director compensation and aligns with standard practices for publicly traded companies.
Stakeholder Impact
- Shareholders may view the stock option grant as a way to align director interests with company performance.
Key Dates
| Date | Description |
|---|---|
| 01/06/2021 | Options to Purchase Common Stock expire 01/06/2026 |
| 06/30/2021 | Options to Purchase Common Stock expire 06/30/2026 |
| 06/30/2022 | Options to Purchase Common Stock expire 06/30/2027 |
| 05/22/2019 | Options to Purchase Common Stock expire 05/22/2024 |
| 08/04/2018 | Options to Purchase Common Stock expire 08/04/2023 |
| 11/30/2020 | Warrants to Purchase Common Stock expire 11/30/2025 |
| 06/30/2024 | Options to Purchase Common Stock expire 06/30/2029 |
| 06/30/2024 | Options to Purchase Common Stock expire 06/30/2029 |
| 09/30/2024 | Director Yun Yen granted stock options to purchase 5,786 shares. |
| 09/30/2024 | Options to Purchase Common Stock expire 09/30/2029 |
| 10/28/2024 | Date of signature for the Form 4 filing. |
Keywords
stock options, director compensation, Form 4, LIXT, Lixte Biotechnology, Yun Yen, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.